Efficacy and safety of denosumab for the treatment of osteoporosis: A systematic review.

Efficacy and safety of denosumab for the treatment of osteoporosis: A systematic review.
Ann Endocrinol (Paris). 2015 Nov 27;
Authors: Diédhiou D, Cuny T, Sarr A, Norou Diop S, Klein M, Weryha G
Abstract
Denosumab is an anti-RANK ligand (RANKL) monoclonal antibody approved for the treatment of postmenopausal osteoporosis and prevention of skeletal metastasis complications. Administered subcutaneously every 6months, it reduces the risk of vertebral fracture by 70% and of hip fracture by 40%. Its safety profile is acceptable. Denosumab may be used to treat patients with moderate to severe renal insufficiency. It has anti-fracture activity equivalent to that of zoledronic acid, but no residual effect, and no action at all beyond 6months. In France, denosumab is reimbursed as a second-line treatment after a first attempt with bisphosphonate.
PMID: 26639186 [PubMed - as supplied by publisher]

Source: Annales d'Endocrinologie - November 27, 2015 Category: Endocrinology Authors: Diédhiou D, Cuny T, Sarr A, Norou Diop S, Klein M, Weryha G Tags: Ann Endocrinol (Paris) Source Type: research